University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

A Study of ENMD-2076 in Ovarian Clear Cell Cancers

Phase 2

Completed

Conditions: Ovarian Clear Cell Carcinoma

Interventions: Drug: ENMD-2076

First Posted Date: 2013-08-02

Last Posted Date: 2019-12-13

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 40

Registration Number: NCT01914510

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
British Columbia Cancer Agency, Vancouver, Alberta, Canada

and more 3 locations

Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues

Phase 4

Conditions: Chronic Hepatitis B

Interventions: Drug: Discontinue NA Treatment
Drug: Continue NA treatment

First Posted Date: 2013-07-30

Last Posted Date: 2015-05-28

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 66

Registration Number: NCT01911156

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Identification of Carnitine-Responsive Cardiomyopathy

Phase 4

Conditions: Carnitine Deficiency

Interventions: Drug: Carnitine

First Posted Date: 2013-07-22

Last Posted Date: 2013-07-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 30

Registration Number: NCT01904396

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Inhalational Anesthesia and Precipitation of Dementia: is There a Link?

Not Applicable

Active, not recruiting

Conditions: Alzheimer's Disease
Dementia

Interventions: Genetic: Blood test
Other: Lumbar spinal tap
Behavioral: Montreal Cognitive Assessment (MOCA) and MMSE

First Posted Date: 2013-07-19

Last Posted Date: 2022-12-05

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 500

Registration Number: NCT01903421

Locations: 🇱🇻
Pauls Stradins Clinical University Hospital, Riga, Latvia
🇨🇦
Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
🇨🇦
William Osler Health Centre, Toronto, Ontario, Canada

Periperal Blood Lymphocytes During Prostate RT

Withdrawn

Conditions: Prostate Cancer

First Posted Date: 2013-07-15

Last Posted Date: 2013-07-15

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT01899391

MRI FDG PET Imaging Cervix

Not Applicable

Completed

Conditions: Cervical Cancer Squamous Cell

Interventions: Biological: 18-FDG PET/CT, DWI, DCE-MRI

First Posted Date: 2013-07-15

Last Posted Date: 2022-11-08

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 25

Registration Number: NCT01899404

Locations: 🇨🇦
University Health Network, The Princess Margaret, Toronto, Ontario, Canada

Post-Thoracotomy Closure Study

Not Applicable

Completed

Conditions: Post Thoracotomy Pain Syndrome

Interventions: Procedure: Pericostal Closure Technique
Procedure: Intracostal Closure Technique

First Posted Date: 2013-07-12

Last Posted Date: 2020-12-08

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 90

Registration Number: NCT01898468

Locations: 🇨🇦
Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures

Phase 3

Completed

Conditions: Non Displaced Atypical Femoral Fractures

Interventions: Other: Placebo
Biological: Teriparatide 20 mcg

First Posted Date: 2013-07-11

Last Posted Date: 2023-06-01

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 34

Registration Number: NCT01896011

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer

Not Applicable

Completed

Conditions: Endometrial Cancer
Sentinel Lymph Node
Indocyanine Green

Interventions: Biological: Indocyanine Green (ICG)

First Posted Date: 2013-06-25

Last Posted Date: 2024-03-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 156

Registration Number: NCT01886066

Locations: 🇨🇦
Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
🇨🇦
University Health Network - Princess Margaret Hospital, Toronto, Ontario, Canada

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Phase 2

Completed

Conditions: Metastatic, Stage III or Stage IV, Melanoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Tumor-Infiltrating Lymphocytes
Biological: Low-Dose Interleukin

First Posted Date: 2013-06-21

Last Posted Date: 2019-11-08

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 12

Registration Number: NCT01883323

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy